Beschreibung
Study design and participant flow for the double-blind, randomized, placebo-controlled trial of Lactobacillus plantarum CCFM1143 in chronic diarrhea are presented. The trial evaluated the probiotic's effects on inflammation regulation and gut microbiota modulation in patients with IBS-D or functional diarrhea.
Figure 1
FlowchartSource Paper
Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study.Cite This Figure
![Figure 1: Study design and participant flow for the double-blind, randomized, placebo-controlled trial of Lactobacillus plantarum CCFM1143 in chronic diarrhea are presented. The trial evaluated the probiotic's effects on inflammation regulation and gut microbiota modulation in patients with IBS-D or functional diarrhea.]() > Source: Bo Yang et al. "Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Re." *Frontiers in immunology*, 2021. PMID: [34721416](https://pubmed.ncbi.nlm.nih.gov/34721416/)
<figure> <img src="" alt="Study design and participant flow for the double-blind, randomized, placebo-controlled trial of Lactobacillus plantarum CCFM1143 in chronic diarrhea are presented. The trial evaluated the probiotic's effects on inflammation regulation and gut microbiota modulation in patients with IBS-D or functional diarrhea." /> <figcaption>Figure 1. Study design and participant flow for the double-blind, randomized, placebo-controlled trial of Lactobacillus plantarum CCFM1143 in chronic diarrhea are presented. The trial evaluated the probiotic's effects on inflammation regulation and gut microbiota modulation in patients with IBS-D or functional diarrhea.<br> Source: Bo Yang et al. "Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Re." <em>Frontiers in immunology</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34721416/">34721416</a></figcaption> </figure>